Structure and Membrane Topography of the Vibrio-Type Secretin Complex from the Type 2 Secretion System of Enteropathogenic Escherichia coli.

The ß-barrel assembly machinery (BAM) complex is the core machinery for the assembly of ß-barrel membrane proteins, and inhibition of BAM complex activity is lethal to bacteria. Discovery of integral membrane proteins that are key to pathogenesis and yet do not require assistance from the BAM complex raises the question of how these proteins assemble into bacterial outer membranes. Here, we address this question through a structural analysis of the type 2 secretion system (T2SS) secretin from enteropathogenic Escherichia coli O127:H6 strain E2348/69. Long ß-strands assemble into a barrel extending 17 Å through and beyond the outer membrane, adding insight to how these extensive ß-strands are assembled into the E. coli outer membrane. The substrate docking chamber of this secretin is shown to be sufficient to accommodate the substrate mucinase SteC.IMPORTANCE In order to cause disease, bacterial pathogens inhibit immune responses and induce pathology that will favor their replication and dissemination. In Gram-negative bacteria, these key attributes of pathogenesis depend on structures assembled into or onto the outer membrane. One of these is the T2SS. The Vibrio-type T2SS mediates cholera toxin secretion in Vibrio cholerae, and in Escherichia coli O127:H6 strain E2348/69, the same machinery mediates secretion of the mucinases that enable the pathogen to penetrate intestinal mucus and thereby establish deadly infections.

Purification and amino acid sequence of vasoactive intestinal peptide, peptide histidine isoleucinamide (1-27) and secretin from the small intestine of guinea pig.

The neuropeptides vasoactive intestinal peptide (VIP) and peptide histidine isoleucinamide (1-27) (PHI) and the hormone secretin were purified from the small intestine of guinea pig, being detected by radioimmunoassay and radioreceptor assay throughout six to seven chromatographic steps. After elution on a reverse-phase C18 column, the three peptides were separated on a Fractogel column. After cation-exchange chromatography of each peptide on Mono S, the final steps were performed using a reverse-phase RP8-e column. Guinea pig PHI differed from porcine PHI in having Tyr and Arg residues instead of Phe and Lys in, respectively, position 10 and 20. We confirmed the original sequence of guinea pig VIP previously documented (with Leu5, Thr9, Met19 and Val26). We also established the similarity of the primary structure of guinea pig secretin with that of porcine and bovine.

A proform of secretin with high secretin-like bioactivity.

A variant form of the heptacosapeptide amide secretin, with C-terminal -Val-Gly-Lys-Arg instead of valine amide, has been isolated from porcine upper intestinal tissue. Unexpectedly, this triacontapeptide exhibited a substantially higher bioactivity than the heptacosapeptide amide.

Production of a biologically active variant form of recombinant human secretin.

A biologically active variant form of recombinant human secretin was produced using a gene fusion system designed to facilitate the purification of the protein. The fusion protein was recovered from the culture medium of Escherichia coli by IgG affinity chromatography, and recombinant secretin was released by cyanogen bromide treatment. A novel approach involving addition of a C-terminal Gly-Lys-Arg extension, was used to overcome the lack of amidation of recombinant proteins in Escherichia coli. The biological activity of the recombinant variant of secretin was at least 80% of the porcine secretin standard.

Presence of biologically and immunologically active secretin-like substance in the mammalian brain.

The present study involves the isolation and characterization of secretin-like immunoreactivity from the brains of pigs, rats and dogs. Secretin-like immunoreactivity was extracted with 0.1 N HCl and subjected to SP-Sephadex ion exchange chromatography and gel filtration on a Sephadex G-50 superfine column. The average amounts of secretin-like immunoreactivity in the extracts of 2 pigs, 7 rats and 6 dog brains were 0.25 ng/g, 2.4 +/- 0.2 ng/g and 0.34 +/- 0.07 ng/g fresh tissue weight, respectively. The secretin-like immunoreactivities in the brain extracts exhibited the same retention coefficient as natural porcine secretin on gel filtration and were eluted in the same salt gradient from the SP-Sephadex column. A partially purified secretin-like immunoreactivity isolated from canine brain exhibited the same bioactivity as natural porcine secretin to stimulate pancreatic volume flow in anesthetized rats (n = 4). These results indicated that secretin-like immunoreactivities from brain extracts possess the same molecular size and charge as natural porcine secretin and the secretin-like immunoreactivity isolated from dog brain is active in stimulating pancreatic secretion in anesthetized rats.

Solid-phase synthesis and biological activities of gastrointestinal hormones: secretin and motilin.

Many successful solid-phase syntheses of peptide chains in the region of 20-40 amino acid residues have now been routinely reported. Utilizing standard solid-phase synthetic methodologies but, particularly, new and powerful purification techniques we have been developing rapid and efficient preparative routes for the numerous neuro-gastrointestinal peptides. In the present study, secretin and motilin were obtained in 16% and 10% yields, respectively, after simplified two-step purification of hydrogen fluoride-cleaved peptides by gel filtration followed by preparation high performance liquid chromatography. Peptides were essentially homogeneous by TLC and analytical high performance liquid chromatography. Secretin was found to have full biological activity when tested against a standard sample of natural material for effects on pancreatic secretion in the dog. Motilin exhibited full biological activity on interdigestive motility in the dog. Secretin has been reported to undergo rearrangement with loss of bioactivity during purification and prolonged storage. We observed no obvious problems during our abbreviated purification schedule and have found no loss of purity of peptide which has been kept for 6 months as power lyophilized from dilute acetic acid.

Amino acid sequence of VIP, PHI and secretin from the rabbit small intestine.

VIP, PHI and secretin were purified from rabbit small intestine throughout a maximum of 6 chromatographic steps. After elution on a reverse phase C18 column, the 3 peptides were separated on a Fractogel column using specific radioimmunoassays for detection. After cation exchange chromatography on Mono S, the final steps were performed using a reverse phase RP8-e column. For these steps, radioreceptor assays were utilized to detect VIP and PHI. We confirmed that the VIP sequence of rabbit was identical to that of porcine VIP. The PHI sequence was also found identical to that of porcine PHI. By contrast, rabbit secretin was highly original, differing from porcine secretin in having Leu, Arg and Leu-NH2 residues instead of Phe, Ser and Val-NH2 in, respectively, position 6, 16 and 27.

Purification and amino acid sequence of vasoactive intestinal peptide, peptide histidine isoleucinamide and secretin from the ovine small intestine.

Vasoactive intestinal peptide (VIP), peptide histidine isoleucinamide (PHI) and secretin were separated and purified to homogeneity from ovine small intestine, using radioimmunoassay and radioreceptor assay for detection. An efficient and rapid purification sequence included acid extraction, concentration on a bulk C18 cartridge, filtration on a Fractogel column, ion-exchange chromatography on Mono-S and a maximum of three successive reverse-phase HPLC steps. The amounts of peptides obtained from 450 g wet weight tissue were 20 micrograms VIP, 15 micrograms PHI and 5 micrograms secretin. The as yet unknown amino acid sequences of the three peptides were found to be identical to those of the corresponding bovine peptides.

Dog secretin: sequence and biologic activity.

Secretin was purified from the first 50 cm of proximal intestine of a single dog. The purification sequence included extraction in acid-ethanol, differential precipitation with acetone, Sephadex gel filtration and three successive HPLC steps. Dog secretin has the following sequence: HSDGTFTSELSRLRESARLQRLLQGLV. The underlined amino acid represents a substitution of Glu for Asp at position 15 from the NH2-terminus of pig secretin. Dog secretin is equal in potency to pig secretin in stimulating pancreatic ductal flow in a rat bioassay system.

Identification of secretin diastereoisomers produced during synthesis.

The byproducts P-1 and P-2, which were produced during the synthesis of porcine secretin, were isolated in pure form from the crude secretin by HPLC. These were identified by a combination of amino acid analysis, enzymatic digestion, and isocratic or linear gradient reversed-phase (RP)-HPLC. The amino acid compositions of P1 and P2, determined by amino acid analysis after acid hydrolysis, were found to be the same as those of porcine secretin without distinction between L-and D-amino acids. But, HPLC of their digestive fragments with trypsin and alpha-chymotrypsin differed from that of secretin. The fragments, S7-12 of P-1 and S13-21 of P-2 were determined to be different from the corresponding fragments obtained from secretin by HPLC analysis of their digestive fragments. The amino acid composition of each acid hydrolysate, following digestion with D-amino acid oxidase, was found to have less leucine or alanine content than secretin. The HPLC analysis of the fragments from P-1 and P-2 by tryptic and alpha-chymotryptic digestion showed that they are the same as those from synthetic D-Leu10 secretin or D-Ala17 secretin, respectively. Consequently, P-1 and P-2 are concluded to be the secretin diastereoisomers, D-Leu10 and D-Ala17 secretin, respectively.

Use of capillary electrophoresis in drug quality assessment of synthetic porcine secretin.

The purity profile for porcine secretin attributable to contamination by equilibrium products such as aspartoyl(3) secretin has been shown to be dependent on the pH of the analytical system. Capillary zone electrophoresis (CZE) methods have been developed for the efficient separation of synthetic porcine secretin, its equilibrium products and other impurities in aqueous solutions at both acidic and alkaline pH. These conditions are more representative of those used for the reconstitution and administration of porcine secretin, and good results cannot be achieved using HPLC due to poor peak shape above pH 5.8. The influence of various CZE operational parameters was systematically examined. The methods were validated for accuracy, precision, linearity, LOD and LOQ. A comparative evaluation of the stability of test solutions was determined using CZE and HPLC over a range of pH values. HPLC and CZE methods produced similar results at low pH.

Secretin responses to feeding and acid load.

Secretin can be readily concentrated from 10 ml of plasma by adsorption to and elution from octadecylsilyl silica columns (C18 Sep-Pak cartridges). This method of concentration is more expedient than either ethanol extraction or adsorption to and elution from precipitated silica (QUSO G32) and permits detection of secretin in plasma at concentrations of 1 pg/ml or greater. Basal secretin in normal subjects was found to be less than 4 pg/ml of plasma. In response to an STM, plasma secretin increased on the average to twice the fasting level, but in response to an oral SAL, it generally increased about 10-fold.

Improvements in the synthesis of secretin by the repetitive excess mixed anhydride (REMA) method.

Protected secretin, a 27-peptide amide, was synthesized by the all-repetitive excess mixed anhydride (REMA) method and purified by preparative reverse-phase high-performance liquid chromatography. Highly potent secretin was obtained after deprotection with the aid of HF/anisole and purification by ion-exchange chromatography. The scope of the REMA-strategy is discussed in comparison with other strategies.

Secretin, its discovery, and the introduction of the hormone concept.

The English physician E. H. Starling discovered in collaboration with the physiologist W. M. Bayliss secretin, the first hormone, in 1902. Three years later they introduced the hormone concept with recognition of chemical regulation, early regulatory physiology took a major step forward. The isolation and subsequent synthesis of secretin in the 1960s prepared the way for immunological techniques. Radioimmuno assays in the 1970s enabled demonstration of a direct endocrine role of secretin. Cloning and molecular hybridisation in the 1990s identified production site structure, precursor and evolutionary relation to other gastrointestinal peptides and to the secretin receptor. Although secretin was the first substance to be established as a hormone, even today our understanding is far from complete.

Isolation and primary structure of rat secretin.

A major form of rat secretin was purified to homogeneity from small intestine, being detected with a porcine secretin radioimmunoassay throughout 7 chromatographic steps. The sequence of the heptacosapeptide amide H-S-D-G-T-F-T-S-E-L-S-R-L-Q-D-S-A-R-L-Q-R-L-L-Q-G-L-V-NH2 shows that rat secretin has a glutamine residue in position 14 instead of arginine as in pig secretin.